CABOMETYX (cabozantinib), tyrosine kinase inhibitor
ONCOLOGY - New medicinal product
Opinions on drugs -
Posted on
Mar 10 2017
Reason for request
Inclusion
Moderate improvement in comparison to AFINITOR in the treatment of advanced or metastatic clear-cell renal cell carcinoma or cancer with a clear-cell contingent, after prior anti-VEGF treatment.
- CABOMETYX has Marketing Authorisation in adults with advanced renal carcinoma after vascular endothelium growth factor (VEGF) receptor targeted therapy.
- Its superiority relative to AFINITOR (everolimus) in terms of progression-free survival and overall survival was established only in the population of patients with advanced or metastatic clear-cell renal cell carcinoma or cancer with a clear-cell contingent, who failed a previous treatment with anti-VEGF.
- This is a second-line treatment in this type of renal cell carcinoma.
Clinical Benefit
Substantial |
- |
Clinical Added Value
moderate |
- |
Therapeutic use
- |
-
Economic analysis
English version
Contact Us
Évaluation des médicaments